Stories
Covid19
Updates: Lilly's Global COVID-19 Response
View Story
Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization
View Story
When the World Called for Help with COVID-19, We Were Ready
View Story
Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody
View Story
An Update on Lilly’s Commitment to Quality Manufacturing
View Story
CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access
View Story
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
View Story
Lilly’s Commitment to Quality Manufacturing
View Story
Lilly Global Day of Service Goes Virtual and Remote to Improve Health, Education and Communities
View Story
Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial
View Story